Metabolism of Oral Turinabol by Human Steroid Hormone-Synthesizing Cytochrome P450 Enzymes.

Drug Metab Dispos

Institute of Biochemistry (L.S., S.B.-A., F.H., J.N., R.B.) and Department of Pharmaceutical Biology (J.Z.), Saarland University, Saarbrucken, Germany; and Institute of Biochemistry, Center for Preventive Doping Research, German Sports University, Cologne, Germany (M.T.)

Published: February 2016

AI Article Synopsis

  • The human mitochondrial enzymes CYP11A1, CYP11B1, and CYP11B2 are key players in steroid hormone synthesis, and this study uncovers their ability to metabolize the doping agent oral turinabol (OT).
  • CYP11B1 and CYP11B2 showed significant catalytic effectiveness in converting OT, with CYP11B2 having the highest efficiency, while CYP11A1 produced several distinct metabolites.
  • The study indicates that these enzymes not only participate in natural steroid functions but also in drug metabolism, highlighting their relevance in drug design and potential toxicity assessments.

Article Abstract

The human mitochondrial cytochrome P450 enzymes CYP11A1, CYP11B1, and CYP11B2 are involved in the biosynthesis of steroid hormones. CYP11A1 catalyzes the side-chain cleavage of cholesterol, and CYP11B1 and CYP11B2 catalyze the final steps in the biosynthesis of gluco- and mineralocorticoids, respectively. This study reveals their additional capability to metabolize the xenobiotic steroid oral turinabol (OT; 4-chlor-17β-hydroxy-17α-methylandrosta-1,4-dien-3-on), which is a common doping agent. By contrast, microsomal steroid hydroxylases did not convert OT. Spectroscopic binding assays revealed dissociation constants of 17.7 µM and 5.4 µM for CYP11B1 and CYP11B2, respectively, whereas no observable binding spectra emerged for CYP11A1. Catalytic efficiencies of OT conversion were determined to be 46 min(-1) mM(-1) for CYP11A1, 741 min(-1) mM(-1) for CYP11B1, and 3338 min(-1) mM(-1) for CYP11B2, which is in the same order of magnitude as for the natural substrates but shows a preference of CYP11B2 for OT conversion. Products of OT metabolism by the CYP11B subfamily members were produced at a milligram scale with a recombinant Escherichia coli-based whole-cell system. They were identified by nuclear magnetic resonance spectroscopy to be 11β-OH-OT for both CYP11B isoforms, whereby CYP11B2 additionally formed 11β,18-diOH-OT and 11β-OH-OT-18-al, which rearranges to its tautomeric form 11β,18-expoxy-18-OH-OT. CYP11A1 produces six metabolites, which are proposed to include 2-OH-OT, 16-OH-OT, and 2,16-diOH-OT based on liquid chromatography-tandem mass spectrometry analyses. All three enzymes are shown to be inhibited by OT in their natural function. The extent of inhibition thereby depends on the affinity of the enzyme for OT and the strongest effect was demonstrated for CYP11B2. These findings suggest that steroidogenic cytochrome P450 enzymes can contribute to drug metabolism and should be considered in drug design and toxicity studies.

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.115.066829DOI Listing

Publication Analysis

Top Keywords

cytochrome p450
12
p450 enzymes
12
cyp11b1 cyp11b2
12
min-1 mm-1
12
oral turinabol
8
cyp11b2
7
cyp11a1
5
metabolism oral
4
turinabol human
4
steroid
4

Similar Publications

Deep Learning of CYP450 Binding of Small Molecules by Quantum Information.

J Chem Inf Model

January 2025

Industrial and Molecular Pharmaceutics, Purdue University, West Lafayette, Indiana 47907, United States.

Drug-drug interaction can lead to diminished therapeutic effects or increased toxicity, posing significant risks, especially in polypharmacy, and cytochrome P450 plays an indispensable role in this interaction. Cytochrome P450, responsible for the metabolism and detoxification of most drugs, metabolizes about 90% of Food and Drug Administration-approved drugs, making early detection of potential drug-drug interactions. Over the years, in-silico modeling has become a valuable tool for predicting drug-drug interactions.

View Article and Find Full Text PDF

Metabolomics and network pharmacology approach to identify potential bioactive compounds from Trichoderma sp. against oral squamous cell carcinoma.

Comput Biol Chem

January 2025

Research Institute of Pharmaceutical Sciences, College of Pharmacy, Chonnam National University, Gwangju 61186, Republic of Korea; Elicure, 12, Gyeongyeol-ro 17 beon-gil, Seo-gu, Gwangju, Republic of Korea. Electronic address:

This study aimed to profile metabolites from five Trichoderma strains and assess their cytotoxic and pharmacological activities, particularly targeting oral squamous cell carcinoma (OSCC). UHPLC-TOF-MS analysis revealed the presence of 25 compounds, including heptelidic acid, viridiol isomers, and sorbicillinol from the different Trichoderma extracts. Pharmacokinetic analysis showed moderate permeability and low interaction with P-glycoprotein, suggesting good drug absorption with minimal interference in cellular uptake.

View Article and Find Full Text PDF

Pylb-based overexpression of cytochrome P450 in Bacillus subtilis 168.

Enzyme Microb Technol

January 2025

Institute of Biotechnology and Genetic Engineering, Chulalongkorn University, Bangkok 10330, Thailand; Center of Excellence in Bioconversion and Bioseparation for Platform Chemical Production, Institute of Biotechnology and Genetic Engineering, Chulalongkorn University, Bangkok 10330, Thailand; Water Science and Technology for Sustainable Environment Research Unit, Chulalongkorn University, Bangkok 10330, Thailand. Electronic address:

Inducer-free expression systems are promising tools for biorefinery because they can reduce the reliance on inducers, reducing production costs and simplifying processes. Owing to their broad range of substrate structures and catalytic reactions, cytochrome P450s are promising biocatalysts to produce value-added compounds. However, unsuitable levels of cytochrome P450 expression could result in cell stress, affecting the efficiency of the biocatalyst.

View Article and Find Full Text PDF

Background: Endocrine-disrupting chemicals (EDCs) interfere with the endocrine system and negatively impact reproductive health. Biochanin A (BCA), an isoflavone with anti-inflammatory and estrogen-like properties, has been identified as one such EDC. This study investigates the effects of BCA on transcription, metabolism, and hormone regulation in primary human granulosa cells (GCs), with a specific focus on the activation of bitter taste receptors (TAS2Rs).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!